Clinical Trial Update: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of ofatumumab in pemphigus vulgaris was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus Vulgaris

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pemphigus | Phase 3 | Status: TERMINATED | Results posted: 2017-06-14